Buy Generic Beloc Online

Generic Beloc Information

Introduction

Beloc is a β‑blocker medication that contains the active compound metoprolol. It belongs to the blood‑pressure therapeutic group and is prescribed primarily for the management of hypertension. Metoprolol also has well‑established roles in the treatment of angina pectoris, chronic heart failure, and certain cardiac arrhythmias, making Beloc a versatile option for cardiovascular care in the United Kingdom. The product is marketed by Abbott Laboratories and conforms to the standards set by the Medicines and Healthcare products Regulatory Agency (MHRA).

What is Beloc?

Beloc is a branded formulation of metoprolol tartrate (immediate‑release) or metoprolol succinate (extended‑release), depending on the specific product strength. Metoprolol is a selective β1‑adrenergic receptor antagonist that reduces heart rate, myocardial contractility, and systemic vascular resistance. The medication is supplied in tablet form, with typical strengths of 25 mg, 50 mg, 100 mg (tartrate) and 25 mg, 50 mg, 100 mg, 200 mg (succinate).

Beloc is manufactured and distributed by Abbott Laboratories, a pharmaceutical company that holds a licence from the MHRA for sale within the UK. The tablets meet the European Pharmacopoeia specifications for purity, dissolution, and stability.

How Beloc Works

Metoprolol blocks β1‑adrenergic receptors located predominantly in cardiac tissue. By inhibiting the action of endogenous catecholamines (adrenaline and noradrenaline), the drug produces three core physiological effects:

1. Negative chronotropy – a reduction in heart‑rate, which decreases cardiac output.
2. Negative inotropy – a modest decline in myocardial contractile force, lowering oxygen demand.
3. Decreased renin release – reduced activation of the renin‑angiotensin‑aldosterone system, contributing to lower systemic blood pressure.

The onset of action for immediate‑release tablets is typically within 30–60 minutes, with peak plasma concentrations at 1–2 hours. Extended‑release formulations provide a more gradual rise in plasma level, allowing once‑daily dosing while maintaining therapeutic concentration for 24 hours. Metoprolol is metabolised primarily by the hepatic cytochromeP450 enzyme CYP2D6 and eliminated via renal excretion; the terminal half‑life ranges from 3 to 7 hours (tartrate) and 5 to 7 hours (succinate) in healthy adults.

Conditions Treated with Beloc

• Essential hypertension – high blood pressure is present in approximately 30 % of the adult UK population, increasing the risk of stroke and myocardial infarction. Metoprolol lowers systolic and diastolic pressures, contributing to cardiovascular risk reduction.

• Stable angina pectoris – by decreasing heart‑rate and contractility, Beloc reduces myocardial oxygen consumption, alleviating chest‑pain episodes.

• Chronic heart failure (NYHA class II–IV) – clinical trials such as MERIT‑HF have demonstrated that metoprolol succinate reduces mortality and hospitalisation in patients with left‑ventricular systolic dysfunction.

• Atrial tachyarrhythmias (e.g., atrial fibrillation, atrial flutter) – β‑blockade controls ventricular rate, improving symptoms and allowing better management of rhythm‑control strategies.

In the UK, prescribing guidelines (NICE CG 127) recommend β‑blockers as first‑line agents for many of these conditions, especially when a patient also requires rate control for atrial fibrillation.

Who is Beloc For?

Beloc is appropriate for adult patients (≥ 18 years) who require pharmacological control of blood pressure, angina, heart failure, or ventricular rate in atrial tachyarrhythmias. Typical clinical scenarios include:

• Individuals with newly diagnosed or uncontrolled hypertension despite lifestyle modification.
• Patients with chronic stable angina who experience exercise‑induced chest pain.
• Adults with left‑ventricular ejection fraction ≤ 40 % who are clinically stable and tolerate β‑blockade.
• Those with atrial fibrillation where rate control is preferred over rhythm control, especially in the presence of hypertension or coronary artery disease.

Contra‑indications and cautions – Beloc should not be initiated in patients with severe bradycardia (heart rate < 50 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, decompensated heart failure, severe asthma or chronic obstructive pulmonary disease with active bronchospasm, and known hypersensitivity to metoprolol or any excipients. Elderly patients, those with hepatic impairment, and individuals taking CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) require dose adjustments and closer monitoring.

Risks, Side Effects, and Interactions

Common

• Fatigue or tiredness – often transient, improves with continued therapy.
• Dizziness, especially on standing – may reflect orthostatic hypotension; advise slow position changes.
• Bradycardia (heart rate < 60 bpm) – usually mild; dose reduction may be needed.
• Cold extremities – reduced peripheral circulation, common with β‑blockade.

Rare

• Depressive symptoms – occasional mood changes reported; monitor patients with a history of depression.
• Sleep disturbance (insomnia or vivid dreams) – may be related to central β‑blockade.
• Gastrointestinal upset (nausea, abdominal pain) – generally mild and self‑limiting.

Serious

• Severe bradycardia (< 40 bpm) or heart block – can precipitate syncope; may require emergency intervention.
• Exacerbation of heart failure – rare, but abrupt discontinuation can precipitate rebound tachycardia and decompensation.
• Bronchospasm or severe asthma attack – β1‑selectivity is not absolute; patients with reactive airway disease should be closely observed.
• Hypotensive crisis – especially when combined with other antihypertensives (e.g., ACE inhibitors, diuretics).

Clinically Relevant Drug Interactions

• CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) increase metoprolol plasma levels → risk of bradycardia and hypotension.
• Other antihypertensives (calcium‑channel blockers such as verapamil, diltiazem) → additive blood‑pressure lowering effect.
• Insulin and oral hypoglycaemics – β‑blockade may mask hypoglycaemic symptoms; glucose monitoring advised.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may reduce the antihypertensive efficacy of metoprolol.
• Concomitant digoxin – risk of increased serum digoxin concentrations; monitor serum levels if both are used.

Patients should provide a complete medication list to their prescriber, including over‑the‑counter products and herbal supplements.

Practical Use: Dosing, Missed Dose, Overdose

• Initial dosing for hypertension – 50 mg once daily (tartrate) or 25 mg once daily (succinate). The dose may be titrated every 2–4 weeks to a maximum of 200 mg per day, depending on blood‑pressure response and tolerance.

• Angina – 50–100 mg twice daily (tartrate) or 25–100 mg once daily (succinate).

• Heart failure (metoprolol succinate) – start at 12.5–25 mg once daily; double the dose every 2 weeks up to a target of 200 mg daily, as tolerated.

• Atrial fibrillation rate control – 25–50 mg twice daily (tartrate) or 25–100 mg once daily (succinate).

Missed dose – If a dose is forgotten within 12 hours, take it as soon as remembered. If more than 12 hours have passed, skip the missed dose and resume the regular schedule. Do not double‑dose.

Overdose – Symptoms may include extreme bradycardia, hypotension, cardiac conduction abnormalities, and respiratory depression. Immediate medical attention is required. Activated charcoal may be considered if ingestion occurred within one hour. Supportive care, atropine, and glucagon are the mainstays of emergency management.

Food and alcohol – Metoprolol may be taken with or without food; however, a high‑fat meal can modestly delay absorption. Alcohol can enhance hypotensive effects; patients should limit alcoholic intake while on therapy.

Comorbidities – Dose adjustments are recommended for patients with renal impairment (creatinine clearance < 30 mL/min) and hepatic dysfunction (Child‑Pugh B or C).

Buying Beloc from Our Online Pharmacy

Beloc can be obtained safely from our online pharmacy in the UK. Our service offers several advantages for patients seeking a reliable source of cardiovascular medication:

• Cost‑effective pricing – We purchase directly from accredited overseas manufacturers, allowing us to sell Beloc at a price close to the manufacturer’s cost, far below typical retail pharmacy rates.
• Verified quality – All batches are sourced from MHRA‑registered suppliers, with certificates of analysis confirming potency, purity, and compliance with EU‑GMP standards.
• Discreet, guaranteed delivery – Orders are packaged in unmarked envelopes and dispatched via secure couriers (7‑day express or approximately 3 weeks regular airmail), ensuring privacy and timely arrival.
• Online‑only accessibility – For patients who encounter limited stock in local pharmacies or face insurance restrictions, our pharmacy broker model connects you with licensed international pharmacies, expanding therapeutic options without compromising safety.

Our pharmacy operates as a broker service that collaborates with overseas licensed pharmacies and respected suppliers. This structure enables a discreet, patient‑centred approach that respects privacy while adhering to all UK import regulations for personal use medications.

FAQ

• Is Beloc available in both brand‑name and generic forms in the UK?
  Yes. Beloc is a brand‑name product that contains the same active ingredient, metoprolol, as generic tablets supplied by various manufacturers. The generic versions are chemically identical and are usually priced lower than the branded product.

• What is the difference between metoprolol tartrate and metoprolol succinate?
  Metoprolol tartrate is an immediate‑release formulation that typically requires twice‑daily dosing, whereas metoprolol succinate is an extended‑release version designed for once‑daily administration. The succinate form provides steadier plasma concentrations, which is advantageous in heart‑failure management.

• How should Beloc be stored during travel abroad?
  Keep the tablets at room temperature (15‑30 °C), away from direct sunlight and moisture. If travelling by air, store the medication in its original container within a carry‑on bag to avoid temperature extremes in the cargo hold.

• Can Belox (Beloc) tablets be crushed or split?
  Immediate‑release tablets may be split if a precise half‑dose is required, provided the tablet is not scored. Extended‑release tablets should never be crushed, chewed, or split, as this can release the entire dose at once and increase the risk of adverse cardiac effects* Are there any excipients in Beloc that could cause allergic reactions?
  In the UK formulation, the inactive ingredients include lactose monohydrate, microcrystalline cellulose, and magnesium stearate. Patients with known lactose intolerance or hypersensitivity to these excipients should discuss alternatives with their prescriber.

• Does Beloc interfere with drug testing for employment or sport?
  Metoprolol is not a prohibited substance under standard workplace drug‑testing panels nor under World Anti‑Doping Agency (WADA) regulations. However, some specialized cardiac‑screening panels may detect β‑blockers, so disclose usage if relevant.

• What are the UK regulations for personal import of Beloc?
  Under the Medicines and Healthcare products Regulatory Agency (MHRA) guidance, a UK resident may import a three‑month supply of a prescription‑only medication for personal use, provided it is accompanied by a valid prescription and the product is not a controlled drug.

• Has the formulation of Beloc changed over time?
  The core active ingredient, metoprolol, has remained constant. Minor formulation updates, such as the switch to a hypoallergenic tablet coating, have occurred to improve tolerability, but the therapeutic effect is unchanged.

• Why might metoprolol dosage need adjustment in older adults?
  Age‑related reductions in hepatic metabolism and renal clearance can raise plasma concentrations, increasing the risk of bradycardia and hypotension. Clinicians therefore start at the lower end of the dosing range and titrate slowly in patients over 65 years.

• Is there any evidence that metoprolol reduces the risk of stroke?
  Large‑scale trials, including the LIFE study, have shown that β‑blockers like metoprolol lower blood‑pressure‑related stroke risk by roughly 15 % compared with placebo, primarily through sustained hypertension control.

• Can Beloc be taken with over‑the‑counter antihistamines?
  Most antihistamines (e.g., cetirizine, loratadine) have minimal cardiovascular effects and are generally safe with metoprolol. However, first‑generation antihistamines (e.g., diphenhydramine) can cause mild sedation and occasional tachycardia; monitor symptoms if co‑administered.

Glossary

β‑blocker

A class of drugs that block beta‑adrenergic receptors, reducing heart‑rate, contractility, and blood‑pressure.

CYP2D6

A liver enzyme that metabolises many medications, including metoprolol; genetic variations can affect drug levels.

Extended‑release (ER)

A formulation designed to release the active ingredient slowly over time, allowing once‑daily dosing.

Orthostatic hypotension

A drop in blood pressure upon standing, leading to dizziness or fainting, often seen with antihypertensive therapy.

⚠️ Disclaimer

The information provided about Beloc is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Beloc for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.